• Explore /
  • Poster
  • / Central nervous system (CNS) outcomes and progression patterns in patients with <em>RET</em> fusion-positive lung cancers treated with selpercatinib.

Central nervous system (CNS) outcomes and progression patterns in patients with RET fusion-positive lung cancers treated with selpercatinib.

Abstract Poster

Authors

null

Yonina R. Murciano-Goroff

Memorial Sloan Kettering Cancer Center, New York, NY

Yonina R. Murciano-Goroff , Christina J. Falcon , Sabrina T. Lin , Aradhika Dhawan , Grace Grimaldi , Dazhi Liu , Clare Wilhelm , Reeja Thomas , Alexia Iasonos , Alexander E. Drilon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3109)

DOI

10.1200/JCO.2022.40.16_suppl.3109

Abstract #

3109

Poster Bd #

101

Abstract Disclosures

Similar Posters

First Author: Igor Odintsov

First Author: Alexander E. Drilon

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Durable efficacy of selpercatinib in patients with <em>RET</em> fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001.

Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001.

First Author: Vivek Subbiah

First Author: Alissa Jamie Cooper